Detection of anti-cytokeratin 8 antibody in the serum of patients with cryptogenic fibrosing alveolitis and pulmonary fibrosis associated with collagen vascular disorders

BACKGROUND It has been suggested that the humoral immune system plays a role in the pathogenesis of cryptogenic fibrosing alveolitis (CFA). Although circulating autoantibodies to lung protein(s) have been suggested, none of the lung proteins have been characterised. The purpose of this study was to...

Full description

Saved in:
Bibliographic Details
Published in:Thorax 1998-11, Vol.53 (11), p.969-974
Main Authors: Dobashi, Naomi, Fujita, Jiro, Ohtsuki, Yuji, Yamadori, Ichiro, Yoshinouchi, Takeo, Kamei, Tadashi, Tokuda, Michiaki, Hojo, Satoko, Okada, Hiroki, Takahara, Jiro
Format: Article
Language:English
Subjects:
A549 cell
Adult
Aged
Aged, 80 and over
antibody
Antigens
Autoantibodies - blood
Biological and medical sciences
Blotting, Western
Collagen Diseases - immunology
collagen vascular disorders
Cytokeratin
cytokeratin 8
Electrophoresis, Polyacrylamide Gel
Enzyme-Linked Immunosorbent Assay
Enzymes
Female
Humans
idiopathic pulmonary fibrosis
Keratins - genetics
Keratins - immunology
Leukemia
Life sciences
Male
Medical sciences
Middle Aged
Monoclonal antibodies
Neutrophils
Original
Patients
Physiology
Pneumonia
Pulmonary Emphysema - immunology
Pulmonary fibrosis
Pulmonary Fibrosis - immunology
RNA, Messenger - genetics
Sarcoidosis, Pulmonary - immunology
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Vein & artery diseases
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND It has been suggested that the humoral immune system plays a role in the pathogenesis of cryptogenic fibrosing alveolitis (CFA). Although circulating autoantibodies to lung protein(s) have been suggested, none of the lung proteins have been characterised. The purpose of this study was to determine the antigen to which the serum from patients with pulmonary fibrosis reacted. METHODS The anti-A549 cell antibody was characterised in a patient with CFA using Western immunoblotting and immunohistochemical staining of A549 cells. As we identified that one of the antibodies against A549 cells was anti-cytokeratin 8, the expression of mRNA of cytokeratin 8 in A549 cells was evaluated. In addition, we attempted to establish an enzyme linked immunosorbent assay to measure the levels of anti-cytokeratin 8 antibody in the serum of patients with CFA and pulmonary fibrosis associated with collagen vascular disorders (PF-CVD). RESULTS Initially two anti-A549 cell antibodies were detected in the serum of patients with pulmonary fibrosis, one of which was characterised as anti-cytokeratin 8 antibody by Western immunoblotting. We were able to establish an ELISA to measure anti-cytokeratin 8 antibody and found significantly higher levels in patients with CFA and PF-CVD than in normal volunteers, patients with sarcoidosis, pneumonia, and pulmonary emphysema. CONCLUSIONS One of the anti-A549 cell antibodies in the serum of patients with CFA was against cytokeratin 8. The serum levels of anti-cytokeratin 8 antibody were increased in patients with CFA and PF-CVD. These results suggest that anti-cytokeratin 8 antibody may be involved in the process of lung injury in pulmonary fibrosis.
ISSN:0040-6376
1468-3296
DOI:10.1136/thx.53.11.969